Through a grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) that was given to the Commonwealth of Pennsylvania, Thomas Jefferson University was awarded a subcontract, averaging about $70,000 per year for three years, to serve as the training center for a suicide prevention project.
Hwyda Arafat, M.D., Ph.D., Associate Professor of Surgery at Thomas Jefferson University, and Mon-Li Chu, Ph.D., Professor and Vice Chair of the Department of Dermatology and Cutaneous Biology, were awarded $200,000 from the University City Science Center’s QED Proof of Concept Program for their breakthrough work on a diagnostic test for pancreatic cancer.
For the last seven years students and faculty from Thomas Jefferson University, including students from Jefferson Medical College (JMC) and the Schools of Nursing, Population Health and Health Professions, have traveled to Rwanda to understand the culture and provide assistance with the healthcare needs of the people of the village of Rugerero, a genocide-survivor village in Northwest Rwanda. Currently three Rwandan medical students are in Philadelphia to learn from Jefferson physicians and share the experience of being a medical student with their American counterparts.
Russell J. Schilder, M.D., recently joined the Kimmel Cancer Center at Jefferson as Director of the Gynecologic Medical Oncology Program, and was also named professor of Medical Oncology and Gynecology at Jefferson Medical College of Thomas Jefferson University in the Department of Medical Oncology.
Researchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with better clinical outcomes. This is a new marker to identify the subset of these patients who may respond positively to chemotherapy.
Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and “Achilles’ heel” of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.
A recent study found no significant difference in the outcome for patients who received carotid artery stenting (CAS) at more than 30 days post-transient ischemic attack (TIA) or stroke versus those who received CAS at 30 days or less post-event.
A new study shows that carotid artery stenting (CAS) following prior same-side carotid artery revascularization is safe, effective and results in lower incidences of in-hospital death, stroke and heart attack compared to first-time CAS for carotid artery stenosis.
This study received “Best of Session” recognition and will be presented in an abstract format at the American Heart Association annual meeting on November 14 at 9:30 AM in Orlando, FL.
Thomas Jefferson University Hospital is the first academic medical center in the United States to offer the recently-approved U.S. Food and Drug Administration (FDA) diagnostic tool that tests melanoma patients for the BRAF mutation (which occurs in about half of all cases) and ultimately determines if they’ll benefit from a new, potentially life-saving drug.
A rise in periprosthetic joint infection (PJI) rates has the orthopedic community moving to develop it’s first-ever agreed upon definition and diagnostic criteria to help better treat patients.
The proposed criteria, published in the November issue of Clinical Orthopaedics and Related Research, was developed by a Musculoskeletal Infection Society working group led by Javad Parvizi, M.D., director of Research at the Rothman Institute at Jefferson. The group analyzed available research, much of which was conducted at Jefferson University Hospital, to develop the new definition and criteria.
Thomas Jefferson University Hospital surgeons found that a carefully-selected surgical care check list of 12 measures reduced Whipple procedure wound infections by nearly 50 percent.
Voichita Bar-Ad, M.D., an associate professor in the Department of Radiation Oncology at Thomas Jefferson University, is one of the select few to be named an “Educator of the Year” by the Association of Residents in Radiation Oncology.
John R. Cohn, MD, head of the Adult Allergy Section at Thomas Jefferson University Hospital and professor of Medicine at Jefferson Medical College of Thomas Jefferson University is one of few allergists to perform the desensitization procedure which trains the body to tolerate aspirin, improving some patients with the triad of sinusitis, asthma, and aspirin-exacerbated respiratory disease (AERD), while allowing others to receive the complete benefits of aspirin for cardiovascular and related disorders.
From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who’ve provided an invaluable contribution to medical science and healthcare.
Andrew Newberg, MD, director of Research, Daniel Monti, MD, medical and executive director and Aleeze Moss, PhD, instructor of the Mindfulness-Based Art Therapy program at the Jefferson-Myrna Brind Center of Integrative Medicine at Thomas Jefferson University Hospital review the most commonly used CAM practices in the management of patients with mood disorders and the available data on CAM use for mood disorders in the recent issue of the Expert Reviews in Neurotherapeutics.
Thomas Jefferson University Hospital (TJUH) is advancing its laboratory testing services with new state-of-the-art equipment from Roche Diagnostics designed to help labs increase their testing capacity and deliver reliable results with greater efficiency. The high-volume, automated system allows patient blood samples to pass through processing, analysis, storage and inventory in a completely cybernated process.
It is a commonly held that information on Wikipedia should not be trusted, since it is written and edited by non-experts without professional oversight. But researchers from the Kimmel Cancer Center at Jefferson have found differently, according to a study published online Sept. 1 in the Journal of Oncology Practice.
Michael L. Oshinsky, Ph.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and a member of the Jefferson Headache Center team, was recently named the 2011 Harold G. Wolff Lecture award recipient for creating a new animal model of migraine headache.
The largest patient population at the Jefferson Voice and Swallowing Center is teachers. The fall season seems to be the heaviest time frame for teacher appointments at the Center.
Kimmel Cancer Center at Jefferson clinical trial found improved overall survival in blood cancer patients who received two-step, half-match bone marrow transplant procedure
Radiation oncologist Robert B. Den, M.D., recently joined Thomas Jefferson University Hospital as an attending physician, and was also named an assistant professor at Jefferson Medical College of Thomas Jefferson University in the Department of Radiation Oncology.
Partnering with the NIH, Thomas Jefferson University successfully tests a vaccine in mice that could lead to a more effective public health tool in Africa.
New research from the Jefferson Heart Institute shows that patients in the United States who receive cardiac electrophysiological devices (CIEDs), including permanent pacemakers and implantable cardioverter-defibrillators (ICDs) are now at greater risk of contracting an infection over the life span of the device.
Thomas Jefferson University received a National Institutes of Health (NIH) $4.8 million grant to test a new rabies vaccine with the potential to cure the virus infection, even after it has made its way into a person’s central nervous system (CNS). Today, if an unvaccinated person is infected with rabies and it spreads to the brain, there is little chance for survival.
David Cognetti, M.D., an otolaryngologist and head and neck specialist at Thomas Jefferson University Hospital in Philadelphia says there is a dramatic increase in the number of patients that he’s seen with HPV-related throat cancer.
He has a patient who is now cancer-free and has started a foundation to help raise money for head and neck cancer patients, as well as to raise awareness of HPV-related head and neck cancer.
Haisong Liu, Ph.D, of the Department of Radiation Oncology at Thomas Jefferson University Hospital, has been named Director of Radiosurgery Physics for the Division of Stereotactic Radiosurgery at Jefferson Hospital for Neuroscience.
Receiving radiation therapy immediately after a radical prostatectomy is a cost-effective treatment for prostate cancer patients when compared with waiting and acting on elevated prostate-specific antigen (PSA) levels, according to a new study by researchers at Thomas Jefferson University and Hospital.
Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.
Walter J. Koch, Ph.D., director of the Center for Translational Medicine at Thomas Jefferson University, will be awarded the prestigious “Outstanding Investigator Award” for 2011 by the International Society for Heart Research (ISHR) for his work in heart failure gene therapy. The award will be presented by the ISHR at its North American meeting in Philadelphia May 22-25.
Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis (MS), and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.
Findings published in the British Journal of Cancer show that damage to surrounding tissue may play role in determining high-grade glioma patients’ long-term outcome.
The recent U.S. Food and Drug Administration (FDA) approval of a brain aneurysm device has opened the door for neurosurgeons at Jefferson Hospital for Neuroscience (JHN) to offer advanced treatment to patients suffering from large or giant aneurysms who otherwise have limited, effective options.
The latest advances in both breast cancer treatment and research – including innovations in diagnostic, surgical, chemotherapy and radiation approaches – will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.
Giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers a wealth of other benefits, say a team of researchers led by Thomas Jefferson University. Their report is published in the March 31st issue of The New England Journal of Medicine (NEJM).